Horizon Pharma To Post Double-Digits Returns, Vetr Crowd Believes

Shares of Horizon Pharma PLC HZNP have lost 4.1 percent in the pat couple of weeks. This, the Vetr crowd seems to believe, has unlocked some room for upside, as evidenced by its average price target of $20.65, which implies a potential return of 13.15 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect the larger upside potential, the Vetr community upgraded its rating on shares of Horizon Pharma on Friday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) – out of a possible 5 Stars rating.

It should be noted that, in accordance with the new score, 80 percent of the crowd’s ratings are bullish at the time.